Multiple firms cleared for Casodex generics in the US
This article was originally published in Scrip
Executive Summary
The US FDA has granted final approval to more than half a dozen applications for bicalutamide 50mg tablets, a generic version of AstraZeneca's prostate cancer treatment Casodex. A key US patent for the innovator, which included paediatric exclusivity, expired in April.